<DOC>
	<DOCNO>NCT02750137</DOCNO>
	<brief_summary>Ametop introduce formulary deem efficacious intravenous cannulation compare EMLA . However , incidence adverse reaction seem high compare study . This lead prospective observational study look incidence severity skin reaction follow routine clinical application Ametop .</brief_summary>
	<brief_title>Ametop - Friend Foe A Prospective Study Incidence Adverse Reactions With Ametop</brief_title>
	<detailed_description>Ametop introduce formulary deem efficacious intravenous cannulation compare EMLA . After several critical incidence adverse reaction occur application , departmental audit carry look incidence severity reaction application well outcome intravenous cannulation . The finding departmental audit show incidence adverse reaction seem occur commonly compare study . A prospective observational study carry look incidence severity skin reaction follow routine clinical application Ametop . This study aim achieve follow : 1 . Investigate incidence severity adverse skin reaction follow topical application Ametop prior intravenous cannulation 2 . Assess success rate intravenous cannulation 3 . Identify possible risk factor associate adverse skin reaction .</detailed_description>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<mesh_term>Tetracaine</mesh_term>
	<criteria>All paediatric patient present surgery August 2014 May 2015 Ametop apply prior intravenous cannulation . Any patient Ametop apply intravenous cannula situ .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Tetracaine</keyword>
</DOC>